PURE-01研究首次生存结果:术前帕博利珠单抗能否带来膀胱切除术后持续缓解?
PURE-01研究纳入143例接受术前帕博利珠单抗后根治性膀胱切除术的患者,中位随访23个月,12和24个月无事件生存率分别为84.5%和71.7%。除ypN+患者外各病理缓解亚组预后良好,临床完全缓解者EFS显著获益,PD-L1 CPS与更长EFS独立相关。
要点
- 术前帕博利珠单抗后24个月EFS为71.7%,多数患者术后维持免疫疗效。
- ypN+患者24个月RFS仅39.3%,为该人群预后不良亚组。
- 临床完全缓解与EFS显著获益相关(P=0.002),PD-L1 CPS高与更长EFS相关。
核心结论
- PURE-01的EFS结果揭示多数患者根治性膀胱切除术后仍维持免疫治疗效应。
- 帕博利珠单抗与新生辅化疗相比结果不劣,且不受生物标志物状态影响。
- 分子分型可能有助于筛选最可能从新辅助帕博利珠单抗获益的患者。
研究设计与样本
- PURE-01研究(NCT02736266)报告次要终点结果,最终分析人群为143例患者。
- EFS定义为从帕博利珠单抗第一周期至影像学进展妨碍RC、启动NAC、RC后复发或任何原因死亡的时间。
- 其他终点包括RFS和OS,并按病理缓解类别、mpMRI评估的临床CR及分子分型进行亚组分析。
主要发现
- 中位随访23个月(IQR 15-29),12个月EFS为84.5%(95%CI 78.5-90.9),24个月EFS为71.7%(95%CI 62.7-82)。
- 除ypN+(N=21)外各病理缓解亚组预后良好,ypN+患者24个月RFS为39.3%(95%CI 19.2-80.5)。
- 临床CR患者EFS获益具有统计学显著性(P=0.002)。
- 多变量分析中PD-L1 CPS与更长EFS显著相关。
- 4例临床CR后拒绝RC的患者中位随访10个月(IQR 11-15)无一复发。
临床怎么用
- 术前帕博利珠单抗可作为肌层浸润性膀胱癌新辅助治疗选择,术后多数患者维持疗效。
- ypN+患者术后复发风险高,需加强随访与辅助治疗评估。
- 临床CR及PD-L1 CPS高表达提示更可能从新辅助免疫治疗中获益。
- 分子分型(如claudin-low)可能辅助筛选新辅助帕博利珠单抗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initial studies of preoperative checkpoint inhibition before radical cystectomy (RC) have shown promising pathologic complete responses. We aimed to analyze the survival outcomes of patients enrolled in the PURE-01 study (NCT02736266). PATIENTS AND METHODS: We report the results of the secondary end points of PURE-01 in the final population of 143 patients. In particular, we report the event-free survival (EFS) outcomes, defined as the time from the first cycle of pembrolizumab to radiographic disease progression precluding RC, initiation of neoadjuvant chemotherapy (NAC), recurrence after RC, or death from any cause. Other end points were recurrence-free survival (RFS) and overall survival (OS). Subgroup analyses were carried out, including pathological response category, clinical complete responses (CR) assessed via multiparametric magnetic resonance imaging (mpMRI), and molecular subtyping. Cox regression analyses for EFS were also carried out. RESULTS: After a median [interquartile range (IQR)] follow-up of 23 (15-29) months, 12- and 24-month EFS were 84.5% [95% confidence interval (CI): 78.5-90.9] and 71.7% (62.7-82). The prognosis was favorable across all the different pathological response subgroups, with the exception of ypN+ (N = 21), showing a 24-month RFS (95% CI) of 39.3% (19.2% to 80.5%). A statistically significant EFS benefit was observed in patients with a clinical CR (P = 0.002). Programmed cell-death-ligand-1 combined positive score was significantly associated with longer EFS in multivariable analyses. Four patients refused RC after clinical evidence of CR, and none of them have recurred after a median follow-up of 10 months (IQR: 11-15). The claudin-low subtype displayed a numerically longer EFS after pembrolizumab and RC compared with the other subtypes. CONCLUSIONS: The EFS results from PURE-01 revealed that the immunotherapy effect was maintained post-RC in most patients. Pembrolizumab compared favorably with neoadjuvant chemotherapy, irrespective of the biomarker status. Molecular subtyping may be a useful tool to select the patients who are predicted to benefit the most from neoadjuvant pembrolizumab.
引用
- Bandini M, Gibb EA, Gallina A, et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆. Ann Oncol. 2020. PMID: 32979511. doi:10.1016/j.annonc.2020.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。